ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.

doi:10.1080/14737159.2025.2576021

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.

Expert review of molecular diagnostics - 1 Dec 2025

Yarunin Alexander, Ahlgren Hanna, Chaki Moumita, Morrow Christopher, Li Xiaodun, Longshore John

Abstract excerpt

INTRODUCTION: Aromatase inhibitors (AI) plus CDK4/6 inhibitors are the current first-line standard-of-care for hormone receptor (HR)-positive/HER2-negative advanced breast cancer (ABC). However, mutations in ESR1 (ESR1m), the gene encoding the estrogen receptor, can drive resistance to AI; their detection in circulating tumor DNA from liquid biopsies may be used to guide treatment. AREAS COVERED: A literature...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Mutation

Share to Sensitivity and Specificity

Source

Open in PubMed

Identifiers

PMID: 41186491
DOI: 10.1080/14737159.2025.2576021

Genes

ESR1
CDK4

Provenance

PubMed metadata and Literature Corpus relationships.